GLCM is pleased to announce that the design of the enhanced graphene sensor used in the Quick Verification Kit, which is an in vitro diagnostic device that produces a sign when exposed to COVID-1nine viral antigens, has been completed. With the full touch of positive identity of viral antigens, GLCM began designing a functional prototype of rapid reaction verification. GLCM hopes to have the wonderful thing about the essentials of regulation and accelerated clinical trials, as announced through several regulators, adding Health Canada and the FDA.
COVID-1nine verification at the GLCM service point will provide exclusive merit for the larger friend over other checks as it detects the presence of the COVID-1nine virus. To date, other advertised competitive controls are the best friendly nucleic acid controls and serological controls. Serological controls are designed to detect the IgM and IgG antibodies that are provided after infection. Nucleic acid checks identify an active infection, however, suntil requires the use of a nasopharyngeal swab and the effects will have to be interpreted through a qualified professional using a beloved device, this is a slow process. Serological and nuclear checks produce false positive and false negative results, while GLCM verification was developed to represent a positive result only when the COVID-1nine virus is provided, allowing transparent interpretation through the user.